GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Addressable Market for ATryn in DIC/Sepsis:

There are approximately 250,000 cases of DIC/sepsis annually in the US and a similar number in Europe (#msg-19928950).

(The number of cases in the US and Europe of severe sepsis per se, with or without DIC, is about 1.5 million annually: #msg-17411076.)

Considering the US market only (where GTC owns 100% of the commercial rights) and assuming a price per treatment of $10,000-$12,000, the addressable market size is (250K)x($10-12K) = $2.5-$3B (#msg-19928950, #msg-22015291).

GTC experts to be able to capture at least $1B of this market opportunity (#msg-19928950).